FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly to pharmacy, and concerns a pharmaceutical composition containing a dimeric dipeptide mimetic BDNF - hexamethylene diamide bis-(N-monosuccinyl-L-seryl-L-lysine) (GSS-106) and as additives - filler, binder and glidant, in amounts specified in claims. Preferably, the filler used is a mixture of lactose and microcrystalline cellulose with particle size of 101 in ratio of 2:1, respectively, as a binder, a copolymer of polyvinyl alcohol and polyethylene glycol, as a sliding substance - magnesium stearate. Pharmaceutical composition is intended for forming tablets and filling capsules.
EFFECT: pharmaceutical composition under the invention extends the range of products with antidepressant activity in a solid dosage form and meets all requirements of GF XIII.
3 cl, 4 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PRODUCING PHARMACEUTICAL COMPOSITION BASED ON HEXAMETHYLENEDIAMIDE BIS-(N-MONOSUCINYL-L-SERYL-L-LYSINE) | 2021 |
|
RU2790827C1 |
| LOW-MOLECULAR MIMETIC BDNF AS AN AGENT FOR TREATING OPIOID DEPENDENCE | 2019 |
|
RU2707301C1 |
| PHARMACEUTICAL COMPOSITION OF NEUROPROTECTIVE ACTION FOR ORAL ADMINISTRATION BASED ON HEXAMETHYLENE AMIDE BIS-(N-MONOSUCCINYL-1-GLUTAMYL-L-LYSINE) (VERSIONS), MADE IN FORM OF A TABLET DISPERSIBLE IN THE ORAL CAVITY | 2018 |
|
RU2740754C1 |
| PHARMACEUTICAL COMPOSITION OF NEUROPROTECTIVE ACTION FOR PARENTERAL APPLICATION ON BASIS OF HEXAMETHYLENEDIAMINE BIS-(N-MONOSUCCINYL-L-GLUTAMIL-L-LYSINE) IN LYOPHILIZED DOSAGE FORM | 2017 |
|
RU2678203C2 |
| AGENT POSSESSING ANTIDIABETIC ACTIVITY | 2017 |
|
RU2693479C2 |
| SUBSTITUTED BISDIPEPTIDE WITH NEUROPROTECTIVE AND ANTIDEPRESSANT EFFECT | 2014 |
|
RU2559880C1 |
| HEPATOPROTECTIVE EFFECT OF LOW MOLECULAR WEIGHT MIMETICS NGF | 2022 |
|
RU2790828C1 |
| PHARMACEUTICAL COMPOSITION BASED ON N-BUTYL-N-METHYL-1-PHENYLPYRROLO[1,2-a]PYRAZINE-3-CARBOXAMIDE | 2023 |
|
RU2811453C1 |
| LOW MOLECULAR WEIGHT MIMETIC OF BRAIN NEUROTROPHIC FACTOR WITH ANALGESIC, ANXIOLYTIC AND ANTIADDICTIVE EFFECTS | 2020 |
|
RU2759023C2 |
| SUBSTANCE WITH ANGIOGENIC ACTIVITY | 2013 |
|
RU2613184C2 |
